
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" article-type="correction" xml:lang="en"><processing-meta tagset-family="jats" base-tagset="archiving" mathml-version="3.0" table-model="xhtml"><custom-meta-group><custom-meta assigning-authority="highwire" xlink:type="simple"><meta-name>recast-jats-build</meta-name><meta-value>1d2b230b09</meta-value></custom-meta></custom-meta-group></processing-meta><front><journal-meta><journal-id journal-id-type="hwp">jitc</journal-id><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="publisher-id">jitc</journal-id><journal-title-group><journal-title>Journal for ImmunoTherapy of Cancer</journal-title><abbrev-journal-title abbrev-type="publisher">J Immunother Cancer</abbrev-journal-title><abbrev-journal-title>J Immunother Cancer</abbrev-journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BMJ Publishing Group Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">jitc-2020-0737-3corr1</article-id><article-id pub-id-type="doi">10.1136/jitc-2020-0737-3corr1</article-id><article-id pub-id-type="pmid">32345628</article-id><article-id pub-id-type="apath" assigning-authority="highwire">/jitc/8/1/e0737-3corr1.atom</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group><subj-group subj-group-type="collection" assigning-authority="publisher"><subject>Open access</subject></subj-group><subj-group subj-group-type="collection" assigning-authority="highwire"><subject>Special collections</subject><subj-group><subject>Open access</subject></subj-group></subj-group></article-categories><title-group><article-title>Correction: <italic toggle="yes">Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers</italic>
</article-title></title-group><pub-date date-type="pub" iso-8601-date="2020-04" pub-type="ppub" publication-format="print"><month>4</month><year>2020</year></pub-date><pub-date date-type="pub" iso-8601-date="2020-04-26" pub-type="epub-original" publication-format="electronic"><day>26</day><month>4</month><year>2020</year></pub-date><pub-date iso-8601-date="2019-12-20T04:54:25-08:00" pub-type="hwp-received"><day>20</day><month>12</month><year>2019</year></pub-date><pub-date iso-8601-date="2019-12-20T04:54:25-08:00" pub-type="hwp-created"><day>20</day><month>12</month><year>2019</year></pub-date><pub-date iso-8601-date="2020-04-28T04:47:36-07:00" pub-type="epub"><day>28</day><month>4</month><year>2020</year></pub-date><volume>8</volume><issue>1</issue><elocation-id>e0737-3corr1</elocation-id><permissions><copyright-statement>© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement><copyright-year>2020</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/" xlink:type="simple"><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2020-04-26">http://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xlink:type="simple">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="jitc-2020-0737-3corr1.pdf" xlink:type="simple"/><custom-meta-group><custom-meta xlink:type="simple"><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Wu H, Chen Y, Wang Z, <italic toggle="yes">et al</italic>. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. <italic toggle="yes">J Immunother Cancer</italic> 2019;7:264. doi: 10.1186/s40425-019-0737-3</p><p>In the article titled ‘Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers’, there is the following errors:</p><p>In the abstract, the sentence ‘Among twenty-one key genes involving in the regulation of DNA methylation, TET1-mutant (TET1-MUT) was enriched in patients responding to ICI treatment in the discovery cohort (p&lt;0.001)’ should instead read ‘Among twenty-one key genes involving in the regulation of DNA methylation, TET1-mutant (TET1-MUT) was enriched in patients responding to ICI treatment in the discovery cohort (p=0.003)’</p><p>Additionally, in Figure 6:</p><list list-type="order"><list-item><p>Line 5, ‘HLA-DQA1’ should be ‘HLA-DQA2’</p></list-item><list-item><p>Line 51–69 (from ENDRB to TIGIT), the category of these genes ‘Other’ should be ‘Receptor’</p></list-item><list-item><p>Line 70–75 (from ARG1 to PRF1), the category of these genes ‘Receptor’ should be ‘Other’.</p></list-item></list><p>The correct Figure 6 can be seen below:</p><p>
<inline-graphic xlink:href="jitc-2020-0737-3corr1ilf01.tif" id="img1" xlink:type="simple"/>
</p></body></article>